Vol. 6 (05) pp. 710-720 DOI: 10.21474/IJAR01/7087

MULTIDRUG RESISTANCE IN PSEUDOMONAS AERUGINOSA: A GENERAL OVERVIEW.

  • Department of Biotechnology, Modern college, Shivaji Nagar, Pune.
15 Downloads 78 Views
Crossref

Download Full Paper (PDF)

Abstract

Pseudomonas aeruginosa, a gram-negative bacillus, is a multidrug resistant (MDR) pathogen posing a threat to hospitalised patients and contributes to their morbidity and mortality. This organism shows a remarkable capacity to resist antibiotics, either intrinsically (because of constitutive expression of β-lactamases and efflux pumps, combined with low permeability of the outer-membrane) or following acquisition of resistance genes (e.g., genes for β-lactamases, or enzymes inactivating aminoglycosides or modifying their target), over-expression of efflux pumps, decreased expression of porins, or mutations in quinolone targets. There has been an accelerated increase in multidrug resistant strains of this organism while the available therapeutic options are severely limited. There is a need for new agents that can overcome the multidrug resistance of these organisms when the available therapeutic options become restricted. This review discusses about various mechanisms of multidrug resistance and possible novel therapeutics introduced from time to time.

Keywords

Article Analytics

References

  1. Alipour M., Halwani M., Omri A. and Suntres Z., ?Antimicrobial Effectiveness of Liposomal Polymyxin B against Resistant Gram-negative Bacterial Strains,? International Journal of Pharmacology 2008; 355 (1-2): 293-298.
  2. Araque M and Velazco E. ?In Vitro Activity of Flerox- acin against Multiresistant Gram-Negative Bacilli Isolated from Patients with Nosocomial Infections,? Intensive Care Medicine 1998; 24(8): 839-844.
  3. Brown A. N., Smith K., Samuels T. A., Lu J., Obare S.O. and Scott M. E., ?Nanoparticles Functionalized with Ampicillin Destroy Multiple-Antibiotic-Resistant Isolates of Pseudomonas aeruginosa and Enterobacter aerogenes and Methicillin-Resistant Staphylococcus aureus,? Appllied and Environmental Microbiology 2012; 78(8): 2768-2774.
  4. Cambray G., Guerout A. M. and Mazel D. Integrons. Annual Review of Genetics 2010; 44: 141?166.
  5. Chen Y. T., Chang H. Y., Lu C. L. and Peng H. L., ?Evolutionary Analysis of the Two-Component System in Pseudomonas aeruginosa PAO1,? Journal of Molecular Evolution 2004; 59(6): 725-737.
  6. Choudhury R. and Srivastava S., ?Zinc Resistance Mechanisms in Bacteria,? Current Science 2001; 81(7): 768-775.
  7. Davies D. G., Parsek M. R., Pearson J. P., Iglewski B. H., Costerton J. W. and Greenberg E. P., ?The Involvement of Cell-To-Cell Signals in the Development of a Bacterial Biofilm,? Science 1998; 280(5361): 295- 298.
  8. Dunne W. M. Jr, Hardin D. J. J. Use of several inducer and substrate antibiotic combinations in a disk approximation assay format to screen for AmpC induction in patient isolates of Pseudomonas aeruginosa, Enterobacter, Citrobacter spp., and Serratia spp. Clinical Microbiology 2005; 43: 5945-5949.
  9. Estiu G., Su?rez D. and Merz K. M. Jr., ?Quantum Mechanical and Molecular Dynamics Simulations of Ureases and Zn Beta-Lactamases,? Journal of Computational Chemistry 2006; 27(12): 1240-1262.
  10. Falagas M. E., Bliziotis I. A., Kasiakou S. K., Samonis G., Athanassopoulou P. and Michalopoulos A. ?Outcome of Infections Due to Pandrug-Resistant (PDR) Gram-Bacteria,? BMC Infectious Diseases 2005; 5(1): 24.
  11. Giedraitiene A., Vitkauskiene A., Naginiene R., and Pavilonis A. Antibiotic resistance mechanisms of clinically important bacteria. Medicina (Kaunas) 2011; 4: 137-146.
  12. Girlich D., Naas T. and Nordmann P. Biochemical characterization of the naturally occurring oxacillinase OXA-50 of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 2004; 48: 2043?2048.
  13. Guespin-Michel J. F., Bernot G., Comet J. P., M?ireau A., Richard A., Hulen C. and Polack B., ?Epigenesis and Dynamic Similarity in Two Regulatory Networks in Pseudomonas aeruginosa,? Acta Biotheoretica 2004; 52(4): 379-390.
  14. Hancock R. E. W. and Brinkman F. Function of Pseudomonas porins in uptake and ef?lux. Annual Review of Microbiology 2002; 56: 17-38.
  15. Hoang T. and Schweizer H., ?Characterization of Pseudomonas aeruginosa Enoyl-Acyl Carrier Protein Reductase (Fabl): A Target for the Antimicrobial Triclosan and Its Role in Acylated Homoserine Lactone Synthesis,? Journal of Bacteriology 1999; 181(17): 5489- 5497.
  16. Holder I. A. Pseudomonas immunotherapy: a historical overview. Vaccine 2004; 22: 831?839.
  17. Huh A. and Kwon Y. ?Nanoantibiotics: A New Paradigm for Treating Infectious Diseases Using Nanomaterials in the Antibiotics Resistant Era,? Journal of Controlled Release 2011; 156(2): 128-145.
  18. Jacoby G. A. Mechanisms of resistance to quinolones. Clinical Infectious Diseases 2005; 41: 120-126.
  19. Kadry A., ?Lack of Efflux Mechanism in a Clinical Isolate of Pseudomonas aeruginosa Highly Resistant to Beta-Lactams and Imipenem,? Folia Microbiologica 2003; 48(4): 529-533.
  20. Karlowsky J. A., Draghi D. C., Jones M. E., Thorns-berry C., Friedland I. R. and Sahm D. F., ?Surveillance for Antimicrobial Susceptibility among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from Hospitalized Patients in the United States, 1998 to 2001,? Antimicrobial Agents and Chemotherapy 2003; 47(5): 1681-1688.
  21. Kobayashi H., Kobayashi O. and Kawai S., ?Pathogenesis and Clinical Manifestations of Chronic Colonization by Pseudomonas aeruginosa and Its Biofilms in the Airway Tract,? Journal of Infection and Chemotherapy 2009; 15(3): 125-142.
  22. Kong K. F., Jayawardena S. R., Del Puerto A, Wiehlmann L., Laabs U., Tummler B. and Mathee K. Characterization of poxB, a chromosomal encoded Pseudomonas aeruginosa Gene 2005; 358: 82?92.
  23. Krivan H. C., Roberts D. D. and Ginsburg V., ?Many Pulmonary Pathogenic Bacteria Bind Specifically to the Carbohydrate Sequence GalNAc Beta 1-4Gal Found in Some Glycolipids,? Proceedings of National Academy of Science 1988; 85(16): 6157-6161.
  24. Lambert P. A. Mechanisms of antibiotic resistance in Pseudomonas aeruginosa. Journal of the Royal Society of Medicine 2002; 95: 22-26.
  25. Lamblin G., Lhermitte M., Klein A., Houdret N., Scharfman A., Ramphal R. and Roussel P., ?The Carbohydrate Diversity of Human Respiratory Mucins: A Protection of the Underlying Mucosa?? The American Review of Respiratory Disease 1991; 144(3): s19-s24.
  26. Landman D., Bratu S., Alam M. and Quale J., ?Citywide Emergence of Pseudomonas aeruginosa Strains with Reduced Susceptibility to Polymyxin B,? Journal of Antimicrobial Chemotherapy 2005; 55(6): 954- 957
  27. Lister P. D., Wolter D. J. and Hanson N. D. Antibacterial-resistant Pseudomonas aeruginosa: Clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clinical Microbiology Review 2009; 22: 582-610.
  28. Malfroot A, Adam G, Ciofu O et al. Immunisation in the current management of cystic fibrosis patients. Journal of Cystic Fibrosis 2005; 4: 77?87.
  29. Moore N. M. and Flaws M. L. Antimicrobial resistance mechanisms in Pseudomonas aeruginosa. Clinical Laboratory Science 2011; 24. 47-51.
  30. Oie S., Uematsu T., Sawa A., Mizuno H., Tomita M., Ishida S., Okano Y. and Kamiya A. ?In Vitro Effects of Combinations of Antipseudomonal Agents against Seven Strains of Multidrug-Resistant Pseudomonas aeruginosa,? Journal of Antimicrobial Chemotherapy 2003; 52(6): 911-914.
  31. Ozer B., Tatman-Otkun M., Memis D. and Otkun M., ?Characteristics of Pseudomonas aeruginosa Isolates from Intensive Care Unit,? Central European Journal of Medicine 2009; 4(2): 156-163.
  32. Poirel L. and Nordmann P. Acquired carbapenem-hydrolyzing β-lactamases and their genetic support. Current Pharmaceutical Biotechnology 2002; 3: 117-127.
  33. Poole K. Pseudomonas aeruginosa: resistance to the max. Frontiers in Microbiology 2011; 2: 65.
  34. Quale J., Bratu S., Gupta J. and Landman D. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrobial Agents and Chemotherapy 2006; 50: 1633-1641.
  35. Rahal J. J. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter Clinical Infectious Diseases 2006; 43(Suppl 2): S95-99.
  36. Schweizer H. P. Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions. Genetics and Molecular Research 2003; 2: 48-62.
  37. Sedlak-Weinstein E, Cripps A. W., Kyd J. M. and Foxwell A. R. Pseudomonas aeruginosa: the potential to immunise against infection. Expert Opinion on Biological Therapy 2005; 5: 967-982.
  38. Singh M., Singh S., Prasad S. and Gambhir I., ?Nanotechnology in Medicine and Antibacterial Effect of Silver Nanoparticles,? Digest Journal of Nanomaterials and? Biostructure 2008; 3(3): 115-122.
  39. Smith R. and Iglewski B., ?Pseudomonas aeruginosa Quorum-Sensing Systems and Virulence.? Current Opinion in Microbiology 2003; 6(1): 56-60.
  40. Soothill J. S., ?Bacteriophage Prevents Destruction of Skin Grafts by Pseudomonas aeruginosa,? Burns 1994; 20(3): 209-211.
  41. Strateva T. and Yordanov D. Pseudomonas aeruginosa ? a phenomenon of bacterial resistance. Journal of Medical Microbiology 2009; 58: 1133?1148.
  42. Tam V. H., Schilling A. N., LaRocco M. T., Gentry L. O., Lolans K., Quinn J. P. and Garey K. W. Prevalence of AmpC over-expression in blood-stream isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 2007; 13: 413-418.
  43. Tamber S, Ochs M. M. and Hancock R. E. W. Role of the novel OprD family of porins in nutrient uptake in Pseudomonas aeruginosa. Journal of Bacteriology 2006; 188: 45-54.
  44. Upadhyay S, Sen MR, Bhattacharjee A. Presence of different beta-lactamase classes among clinical isolates of Pseudomonas aeruginosa expressing AmpC beta-lactamase enzyme. The Journal of Infection in Developing Countries 2010; 4: 239-242.
  45. Vasil M. L., ?How We Learnt about Iron Acquisition in Pseudomonas aeruginosa: A Series of Very Fortunate Events,? Biometals 2007; 20(3-4): 587-601.
  46. Verma A. and Rampal R. ?Glycosylation Islands of Pseudomonas Species,? In: J. L. Ramos and A. Filloux, Eds., Pseudomonas, Springer Netherland, Dordrecht, 2007, pp. 31-56.
  47. Wilke M. S., Lovering A. L. and Strynadka N. C. J. ?β-Lactam Antibiotic Resistance: A Current Structural Perspective,? Current Opinion in Microbiology 2005; 8(5): 525-533.
  48. Wr?blewska M., ?Novel Therapies of Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter Infections: The State of the Art,? Archivum Immunologiae et Therapia Experimentalis 2006; 54(2): 113- 120.
  49. Zhang L., Pornpattananangkul D., Hu C.M. and Huang C.M., ?Development of Nanoparticles for Antimicrobial Drug Delivery,? Current Medicinal Chemistry 2010; 17(6): 585-594.
  50. Zhang S., McCormack F., Levesque R., O?Toole G. and Lau G., ?The Flagellum of Pseudomonas aeruginosa Is Required for Resistance to Clearance by Surfactant Protein A,? Public Library of Science 2007; 2(6): 564.

How to Cite This Article

Abbas Omran. (2018); MULTIDRUG RESISTANCE IN PSEUDOMONAS AERUGINOSA: A GENERAL OVERVIEW., Int. J. of Adv. Res., 6 (05), 710-720, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/7087

Corresponding Author

Abbas Omran
Department of Biotechnology, Modern college, Shivaji Nagar, Pune
Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.